CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer

Poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors benefit a small percentage of ovarian Cancer patients with homologous recombination (HR) deficiency (HRD), which greatly limits the applications of PARP inhibitors. Given the function of CDK9 in homologous recombination repair (HRR), here, we show how to extend the utility of PARP inhibitors in BRCA1-proficient ovarian Cancer by targeting CDK9. We found that high CDK9 expression is associated with a higher tumor stage in epithelial ovarian Cancer patients, and CDK9 is co-expressed with BRCA1 by analyzing a public database. By using a CDK9 Inhibitor CDKI-73, we found that its combination with the PARP Inhibitor olaparib significantly suppressed cell viability and colony formation and induced Apoptosis in BRCA1-proficient ovarian Cancer cells. Consistently, the combination treatment remarkably reduced the tumor growth in mouse xenograft models. We demonstrated that CDKI-73 could downregulate BRCA1 expression, resulting in hypersensitivity to olaparib in BRCA1-proficient ovarian Cancer. Taken together, our results show a synergetic effect of CDKI-73 combined with olaparib in BRCA1-proficient ovarian Cancer, facilitating the clinical use of CDK9 as a predictive biomarker to exploit PARP inhibitors.